The chief executive of the biotechnology industry’s top lobbying group in Washington is on leave amid dissent within the organization about its direction and concern about its results, according to people familiar with the group. “The BIO CEO is currently on leave,” a spokesman for the Biotechnology Innovation Organization said in response to inquiries from The Wall Street Journal. She and some board members clashed on multiple fronts, people familiar with the matter said. Some board members expressed concerns about her performance and management style, people familiar with the matter said. Before joining BIO, Dr. McMurry-Heath worked at Johnson & Johnson and at the Food and Drug Administration.

Source: Wall Street Journal October 09, 2022 18:30 UTC